DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
Department of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Strahlenther Onkol. 2023 Nov;199(11):1018-1024. doi: 10.1007/s00066-023-02136-z. Epub 2023 Sep 12.
Electroanatomical mapping (EAM)-guided stereotactic arrhythmia radioablation (STAR) is a novel noninvasive therapy option for patients with monomorphic ventricular tachycardia (VT) refractory to antiarrhythmic drugs and/or urgent catheter ablation (CA). Data on success rates in an emergency situation such as electrical storm (ES) are rare. We present a case of a patient with an initially very poor life expectancy after extensive myocardial infarction with therapy-resistant ES, not amendable for further antiarrhythmic drug therapy, implantable cardioverter-defibrillator implantation, or repeated CA who was introduced to the radiation oncology department for emergency STAR as a bail-out therapy.
Target volume definition and transfer from EAM to CT were validated and quality assured with a semi-automatic, dedicated visualization tool (CARDIO-RT). Emergency STAR was performed with 25 Gy in the framework of the RAVENTA study. The VT burden gradually decreased after STAR; however, a second VT morphology occurred, which was successfully treated with EAM-guided CA 12 days after STAR.
The second EAM-guided CA showed areas of low voltage in the irradiated segments, indicating a precise targeting and early functional response to STAR. The patient remained free of any VT recurrence or any radiation-related toxicities and in good general condition during the recent follow-up of 18 months.
The case highlights the possible approach, caveats, difficulties, and prognosis of a patient severely affected by therapy-resistant VT in whom CA could not lead to VT suppression. Further studies of putative mechanisms of STAR in the acute and chronic phase of this novel therapy are warranted.
电解剖标测(EAM)引导的立体定向心律失常放射消融(STAR)是一种新型的非侵入性治疗选择,适用于抗心律失常药物和/或紧急导管消融(CA)治疗无效的单形性室性心动过速(VT)患者。在电风暴(ES)等紧急情况下的成功率数据很少。我们报告了一例患者,该患者广泛心肌梗死后出现 ES,且对治疗有抵抗,预期寿命极短,无法进一步接受抗心律失常药物治疗、植入式心脏复律除颤器植入或重复 CA,因此被介绍到放射肿瘤科进行紧急 STAR 治疗,作为一种挽救治疗。
使用半自动专用可视化工具(CARDIO-RT)验证并保证目标容积的定义和从 EAM 到 CT 的转移。在 RAVENTA 研究中,以 25Gy 进行紧急 STAR。STAR 后 VT 负荷逐渐减少,但出现第二种 VT 形态,随后进行 EAM 引导的 CA,12 天后成功治疗。
第二次 EAM 引导的 CA 显示在照射节段存在低电压区域,表明 STAR 具有精确的靶向性和早期的功能反应。在最近 18 个月的随访中,患者无任何 VT 复发或任何与辐射相关的毒性,且一般状况良好。
该病例强调了一种可能的方法、注意事项、困难和预后,对于严重受治疗抵抗性 VT 影响的患者,CA 无法抑制 VT,STAR 可能是一种新的治疗方法。需要进一步研究这种新型治疗方法的急性期和慢性期的 STAR 潜在机制。